State University of New York, Brooklyn   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Brooklyn NY United States (1860)

Organization Overview

First Clinical Trial
1983
NCT00000585
First Marketed Drug
1994
fludeoxyglucose f-18
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Department of Dermatology, State University of New York | DOWNSTATE CLINCL | Downstate Medical Center | Marina Boruk | Nand Wadhwa | New York Health Science Center | Stae University of New York Downstate Medical Center | Staten Island University Hospital | State University of New York Downstate | State University of New York - Downstate Medical Center | SUNY Downstate | SUNY Downstate Med Ctr | SUNY Downstate Medical | SUNY Downstate Medical Center Department of Anesthesiology | SUNY Downstate Medical Center, University Hospital of Brooklyn | SUNY Health Science Center, Brooklyn

Active Ingredients

Marketed Drugs (1)

fludeoxyglucose f-18 (1994)

Drugs in Phase 4 Trials (10)

carvedilol (coreg) (1 trial)

dexmedetomidine (precedex) (1 trial)

doxercalciferol (hectorol) (1 trial)

gabapentin (neurontin) (1 trial)

insulin human (humulin) (1 trial)

metoprolol (lopressor) (1 trial)

minocycline (minocin) (4 trials)

propofol (diprivan) (2 trials)

sevoflurane (ultane) (1 trial)

tazarotene (tazorac) (1 trial)

Drugs in Phase 3 Trials (9)

autologous mononuclear stem cell (1 trial)

bortezomib (velcade) (1 trial)

hydroxyurea (hydrea) (2 trials)

lenalidomide (revlimid) (2 trials)

leuprolide (lupron) (1 trial)

norethindrone (1 trial)

procaine benzylpenicillin (novocaine) (1 trial)

triamcinolone (kenalog) (1 trial)

urea (1 trial)

Drugs in Phase 2 Trials (16)

alprazolam (xanax) (1 trial)

caffeine (1 trial)

calcium citrate (1 trial)

doxapram (dopram) (1 trial)

doxycycline (vibramycin) (2 trials)

ethanol (1 trial)

helium (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

ibuprofen (motrin) (1 trial)

ketorolac (acuvail) (1 trial)

levoleucovorin (fusilev) (2 trials)

lidocaine (xylocaine) (2 trials)

menthol (Salonpas) (1 trial)

onabotulinumtoxinA (Botox) (1 trial)

oxygen (1 trial)

sodium chloride (1 trial)

Drugs in Phase 1 Trials (3)

codeine (Phenergan) (1 trial)

emricasan (1 trial)

scd-101 (1 trial)

Drugs in Other Trials (7)

aprepitant (Emend) (1 trial)

cephalexin (keflex) (1 trial)

clindamycin (cleocin) (1 trial)

cyanocobalamin (berocca) (1 trial)

fish oil (Omegavan) (1 trial)

kibow biotics (1 trial)

ranolazine (ranexa) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 4)

Anemia (Phase 3)

Anemia, Sickle Cell (Phase 3)

Apnea (Phase 2)

Asthma (Phase 2)

Autism Spectrum Disorder (Phase 2)

Autistic Disorder (Phase 2)

Child Development Disorders, Pervasive (Phase 2)

Disease (Phase 2)

Dysmenorrhea (Phase 3)

Dyspareunia (Phase 3)

Endometriosis (Phase 3)

Hematologic Diseases (Phase 3)

Hemoglobinopathies (Phase 3)

Hypertension (Phase 4)

Insulin Resistance (Phase 4)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 4)

Language Disorders (Phase 2)

Multiple Myeloma (Phase 3)

Nasal Polyps (Phase 3)

Neoplasms, Plasma Cell (Phase 3)

Pain, Postoperative (Phase 4)

Panic Disorder (Phase 2)

Pneumonia (Phase 3)

Pruritus (Phase 2)

Psoriasis (Phase 2)

Renal Insufficiency, Chronic (Phase 4)

Retinopathy of Prematurity (Phase 2)

Rhinitis (Phase 2)

Rhinitis, Allergic (Phase 2)

Sleep Apnea, Obstructive (Phase 2)

Sleep Apnea Syndromes (Phase 2)

Syndrome (Phase 2)

Thalassemia (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 38
  • # of Trial APIs: 45